Exscientia Files For $100M IPO

  • Exscientia, the U.K.-based artificial intelligence-driven pharmatech firm, submitted its F-1 on Friday, penciling an initial $100 million estimated proceeds.
  • The company plans to list on NASDAQ under the symbol EXAI.
  • Exscientia offers an AI-centric drug discovery platform for the invention of new drugs, designing therapeutics. It has built a complete end-to-end solution of AI and experimental technologies for target identification, drug candidate design, translational models, and patient selection.
  • Exscientia states that it has originated the first three AI-designed precision drug candidates to enter human clinical trials. Its most advanced internally developed candidate, EXS21546, began a Phase 1 trial in December 2020.
  • The other two candidates, developed by its collaboration partner Sumitomo Dainippon Pharma, are also currently in Phase 1 trials. 
  • Exscientia has designed four additional candidates currently undergoing advanced profiling for submission of INDs, with more than 25 active projects in total.
  • Related: Exscientia expanded a Celgene-era deal with Bristol Myers Squibb.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFinancingOfferingsIPOsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!